800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial
Authors: HALUZIK MARTIN , FRIAS JUAN P. , CHENG ALICE Y. , AL-SOFIANI MOHAMMED , LAUAND FELIPE , MELAS-MELT LYDIE , SOUHAMI ELISABETH , ROSENSTOCK JULIO 
Published: June 2023

We aimed to evaluate derived Time in Range (dTIR) and identify predictors for achieving HbA1c and dTIR targets after commencing iGlarLixi in people with type 2 diabetes (T2D).

These exploratory analyses of LixiLan-L, an open-label, randomized trial, included people with T2D advancing from basal insulin ± oral agents. dTIR (70−180 mg/dL), derived Time above Range (dTAR, &gt;180 mg/dL), and derived Time below Range (dTBR, &lt;70 mg/dL) were calculated from the 7-point SMBG profiles. HbA1c and dTIR were assessed at Week 30. Predictive factors for achieving targets were analyzed with univariable and multivariable stepwise logistic regression.

Participants receiving iGlarLixi (n=366) showed an increase in dTIR from 64% at baseline (BL) to 82%, with 66% achieving dTIR ≥70% and 50% achieving clinically significant improvements (≥5% dTIR) at Week 30. The dTIR &gt;70%, dTBR &lt;4%, and dTAR &lt;25% triple target was attained by 54% of participants receiving iGlarLixi. Weight change from BL, and lower HbA1c and total daily insulin dose at BL were predictors for attaining HbA1c &lt;7.0%; lower BL HbA1c was a predictor of dTIR ≥70% (Table).

In conclusion, iGlarLixi is associated with clinically significant HbA1c and dTIR improvements in T2D advancing from basal insulin. Lower BL HbA1c predicted achieving HbA1c &lt;7.0% and dTIR ≥70% goals, whereas lower BL insulin dose predicted achieving HbA1c &lt;7.0% only.

Disclosure

M.Haluzik: Advisory Panel; Novo Nordisk, Lilly Diabetes, Boehringer-Ingelheim, Research Support; Sanofi, Speaker's Bureau; Abbott, AstraZeneca. J.P.Frias: Advisory Panel; Becton, Dickinson and Company, Pfizer Inc., Sanofi, Consultant; Akero Therapeutics, Inc., 89bio, Inc., Aimmune, Boehringer Ingelheim Inc., Eli Lilly and Company, Carmot Therapeutics, Inc., Echosens, Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Pfizer Inc., Sanofi, Employee; Ionis Pharmaceuticals, Research Support; Akero Therapeutics, Inc., 89bio, Inc., Altimmune, Axcella Health Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Intercept Pharmaceuticals, Inc., Carmot Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Metacrine, Inc., Novo Nordisk, Oramed Pharmaceuticals, Novartis, Pfizer Inc., Sanofi, Speaker's Bureau; Eli Lilly and Company, Sanofi. A.Y.Cheng: Advisory Panel; Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc., Other Relationship; Diabetes Canada, Research Support; Applied Therapeutics Inc., Speaker's Bureau; Abbott, AstraZeneca, Bayer Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., HLS Therapeutics Inc., Medtronic, Novo Nordisk, Sanofi, Insulet Corporation, Dexcom, Inc., Bausch Health, Canada. M.Al-sofiani: Consultant; Eli Lilly and Company, Speaker's Bureau; Sanofi, Medtronic, Vitalair. F.Lauand: Employee; Sanofi. L.Melas-melt: None. E.Souhami: Employee; Sanofi, Stock/Shareholder; Sanofi. J.Rosenstock: Advisory Panel; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Novo Nordisk, Oramed Pharmaceuticals, Sanofi, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Hanmi Pharm. Co., Ltd., Research Support; Applied Therapeutics Inc., Boehringer Ingelheim Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer Inc., Sanofi, Intarcia Therapeutics, Inc.

Funding

Sanofi